Apr 10, 2013 - Benjamin H Chi8,9, John R Koethe3,8, Donna K Arnett10 and Edmond ...... 6. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, ...
Kiage et al. Lipids in Health and Disease 2013, 12:50 http://www.lipidworld.com/content/12/1/50
RESEARCH
Open Access
Cardiometabolic risk factors among HIV patients on antiretroviral therapy James N Kiage1, Douglas C Heimburger1,4,5, Christopher K Nyirenda6, Melissa F Wellons2, Shashwatee Bagchi7, Benjamin H Chi8,9, John R Koethe3,8, Donna K Arnett10 and Edmond K Kabagambe1,10*
Abstract Background: HIV and combination antiretroviral therapy (cART) may increase cardiovascular disease (CVD) risk. We assessed the early effects of cART on CVD risk markers in a population with presumed low CVD risk. Methods: Adult patients (n=118) in Lusaka, Zambia were recruited at the time of initiation of cART for HIV/AIDS. Cardiometabolic risk factors were measured before and 90 days after starting cART. Participants were grouped according to cART regimens: Zidovudine + Lamivudine + Nevirapine (n=58); Stavudine + Lamivudine + Nevirapine (n=43); and ‘other’ (Zidovudine + Lamivudine + Efavirenz, Stavudine + Lamivudine + Efavirenz, Tenofovir + Emtricitabine + Efavirenz or Tenofovir + Emtricitabine + Nevirapine, n=17). ANOVA was used to test whether changes in cardiometabolic risk markers varied by cART regimen. Results: From baseline to 90 days after initiation of cART, the prevalence of low levels of high-density lipoprotein cholesterol (
